Regulacje i polityka gospodarcza · 07/12/2015

National Cancer Institute to Grant ElexiMed LLC Exclusive Evaluation Option License for Renal Cancer Treatment

The National Cancer Institute is considering granting ElexiMed LLC, a company based at 5003 Green Mountain Circle, Suite 4, Columbia, MD 21044, USA, an exclusive evaluation option license to develop and commercialize Aza-Epoxy Guaiane Derivatives for the treatment of renal cancer, based on patent applications filed in 2014 and 2015.